Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Executive summary

Budget impact of Descartes-08

1 evidence topic · 19 sources

Summary

The report holds no budget impact model and no announced price for Descartes-08; the company states that it has no products approved for sale and has not generated any product sales. The inputs a model would draw on are quoted elsewhere in the report:

  • Eligible population: ICER's 2021 budget impact analysis estimated 46,870 U.S. patients with gMG (MGFA clinical classification II to IV), assumed that 100% would be diagnosed, and assumed that 20% would initiate the new treatment in each of five years (9,374 additional patients per year). ICER states that approximately 80% of patients with generalized MG have AChR autoantibodies; a November 2026 company presentation gives a share of about 85% with AChR antibodies, citing Lazaridis et al., 2020, and AURORA is designed for participants with AChR antibody-positive MG. The company estimates that MG affects over 106,000 patients in the U.S., and a study of MarketScan databases estimated approximately 82,715 U.S. adults living with MG in 2021. Among 782 participants in a survey study, 49 (6%) had refractory gMG at enrollment and 201 (26%) were classified as ever-refractory. Among 8759 adults with gMG in Komodo Research Data, use of C5 inhibitors rose from 0.3% to 3.4% and of FcRn blockers from 0.3% to 3.8% between the first and fifth treatment episodes.
  • Dosing: AURORA administers Descartes-08 as six once-weekly infusions without preconditioning chemotherapy, and the company describes it as designed for outpatient administration. A company presentation cites projections “inclusive of opportunity to retreat patients”.
  • Comparator costs: wholesale acquisition costs of $6,314.19 per vial of Vyvgart (2 or 3 vials per dose, weight based) as of September 30, 2025, $16,410.23 per vial and $17,066.64 per syringe of Vyvgart Hytrulo (1 per dose) as of October 1, 2026, and $140,248.50 per dose of Uplizna (2025); a price of $6,523 per single-dose vial of Soliris (2025). One study estimated the annual cost of health-care-provider-administered gMG treatment at $223,272 to $648,960 depending on drug and body weight.
  • Cell therapy costs: among 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma, the median cost of CAR-T products was $402 500 and median total costs $608 100. Across 391 Medicare CAR-T claims, the average Medicare cost was US$498,723 in the inpatient setting and $414,393 in the outpatient setting. CMS pays an inpatient CAR-T case through a single DRG payment for the stay and a solely outpatient case at Average Sales Price plus 6%; in the FY 2027 final rule, CMS estimated average costs of $410,125 for nonclinical trial cases assigned to MS-DRG 018. Costs of cilta-cel therapy excluding product acquisition were estimated at US$160,933 over 12 months, including $18,268 in pre-infusion costs such as apheresis.
  • Budget thresholds in prior ICER assessments: 8.8% of the eligible gMG population could be treated with efgartigimod at its placeholder price without passing ICER's budget impact threshold, and 43% of eligible multiple myeloma patients could be treated with ide-cel at its list price of $419,500 within five years before crossing the threshold of $819 million per year.